In a recent Original Investigation published in AJKD, David Bushinsky and colleagues characterized the effect of patiromer on serum phosphorus in patients with CKD, hyperkalemia, and hyperphosphatemia.

Figure 1 from Bushinsky et al, AJKD © The Authors

AJKD’s Social Media Editor, Timothy Yau @Maximal_Change recently sat down with his Rush Nephrology colleagues Pravir Baxi @Proximal_Baxi, Roger Rodby @NephRodby, and William Whittier @TWhittier_RUSH, for a deeper dive into hyperkalemia and potassium binders.

If the embedded player above doesn’t work, please click here to watch the video interview. Special thanks to Drs. Baxi, Rodby, and Whittier for lending us their expertise!

To view this Original Investigation [Open Access], please visit AJKD.org.
Title: Patiromer Treatment in Patients With CKD, Hyperkalemia, and Hyperphosphatemia: A Post Hoc Analysis of 3 Clinical Trials
Authors: David A. Bushinsky, Jeffrey J. Budden, Philip A. Kalra, Jinwei Yuan, Carol Moreno Quinn, and Murray Epstein
DOI: 10.1053/j.ajkd.2023.01.444